Media Notification/Webcast Notification - Amgen and Abgenix to Conduct Conference Call and Webcast Regarding Panitumumab Pivotal Study Results - November 3, 2005, 8:00 am PT
THOUSAND OAKS & FREMONT, Calif.--(BUSINESS WIRE)--Nov. 3,
2005--Amgen (Nasdaq:AMGN) and Abgenix, Inc. (Nasdaq:ABGX) will host a
joint conference call on November 3 at 8:00 a.m. Pacific Time to
discuss the top-line results of a recently completed pivotal study of
panitumumab. A separate press release announcing these results is
being issued this morning.
Live audio of the conference call will be simultaneously broadcast
over the Internet and will be available to members of the news media,
investors and the general public.
To participate in the conference call, please dial 877-817-2450 or
706-634-7548 fifteen minutes before start time. The pass code for the
live call is 2201994. A telephonic replay of the call will be
available by dialing 800-642-1687 or 706-645-9291. The replay
participant code is 2201994.
The webcast of the conference can be found on Amgen's Web site,
www.amgen.com, under Investors, and on Abgenix's Web site,
www.abgenix.com. The webcast will be archived and available for replay
at least 72 hours after the event.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of fully human therapeutic antibodies.
The company's antibody development platform includes a leading
technology and state-of-the-art manufacturing capabilities that enable
the rapid generation, selection and production of high affinity, fully
human antibody product candidates to a variety of disease targets.
Abgenix leverages its leadership position in human antibody technology
to build a diversified product portfolio through its own development
efforts and the establishment of collaborations with multiple
pharmaceutical and biotechnology companies. For more information on
Abgenix, visit the company's website at www.abgenix.com.
CONTACT: Amgen, Thousand Oaks
Trish Hawkins, 805-447-4587 (media)
Arvind Sood, 805-447-1060 (investors)
Greg Mann, 510-284-6566 (media & investors)